Donor cell infusion (DCI) is planned. Would I still benefit from DLI

TL;DR: DCI (donor cell infusion) and DLI (donor lymphocyte infusion) serve different purposes—DCI gives you new stem cells, while DLI boosts immune attack on your cancer—and you may benefit from BOTH, either sequentially or together, depending on how you respond to DCI.

---

KEY POINTS:

• DCI and DLI are complementary, not competing therapies — DCI rebuilds your bone marrow, DLI enhances immune control of your disease
• Your mixed chimerism + del(7q) relapse makes you a candidate for both — this combination is standard post-transplant relapse strategy
• DLI timing depends on your DCI response — if DCI works well, DLI may consolidate remission; if DCI doesn't work, DLI may be tried earlier
• Your cardiac status affects both decisions — both therapies can cause complications in your severely compromised heart
• You need to ask your oncologist explicitly whether DLI is planned — this should be part of your overall post-transplant relapse strategy

NEXT STEP: Ask your oncologist: "Is DLI part of my treatment plan? If so, when would it be given relative to DCI, and what would be the goal?"

---

FULL ANSWER

---

Understanding DCI vs. DLI: Two Different Therapies with Different Goals

You're asking an excellent question that gets at the heart of post-transplant relapse management. Let me clarify what each therapy does, why they're different, and whether you'd benefit from both.

First, the critical distinction:

| Therapy | What It Is | What It Does | Goal | |---|---|---|---| | DCI (Donor Cell Infusion) | Fresh stem cells from your original donor | Rebuilds your bone marrow; restores hematopoiesis (blood cell production) | Restore normal blood counts; achieve full donor chimerism | | DLI (Donor Lymphocyte Infusion) | Immune cells (T cells, B cells) from your original donor | Boosts graft-versus-leukemia (GVL) effect; uses donor immune system to attack your MDS clone | Attack residual disease; prevent relapse |

They work on different principles and target different problems.

---

1) Your Specific Situation: Why Both Therapies May Be Relevant

Your medical profile creates a situation where BOTH DCI and DLI could be beneficial:

Problem 1: Your Mixed Chimerism (Why You Need DCI)

You have mixed donor chimerism, meaning:

• Your bone marrow is a mixture of donor cells and your own cells
• Your donor cells are not fully engrafted
• Your CD34 count is 0% donor cells (very poor stem cell recovery)

What this means:

According to NCCN Post-Transplant Relapse Guidelines and ASTCT (American Society for Transplantation and Cellular Therapy) recommendations:

• Mixed chimerism indicates incomplete graft engraftment
• Your bone marrow is not being adequately rebuilt by donor cells
• DCI (donor cell infusion) is indicated to restore full donor chimerism

DCI will:

• Provide fresh donor stem cells to repopulate your bone marrow
• Shift you from mixed chimerism toward full donor chimerism
• Restore normal blood cell production (addressing your cytopenias)

This is why your oncologist is planning DCI.

Problem 2: Your del(7q) Relapse (Why You Need DLI)

You have del(7q) in 96% of your cells post-transplant, which means:

• Your MDS clone has relapsed or persisted despite transplant
• Your donor's immune system hasn't adequately controlled your disease
• You need enhanced graft-versus-leukemia (GVL) effect

What this means:

According to NCCN Post-Transplant Relapse Guidelines:

• Disease relapse post-transplant indicates inadequate GVL effect
• DLI (donor lymphocyte infusion) is indicated to boost immune attack on your disease
• DLI is particularly effective for MDS relapse (response rates 30-50%)

DLI will:

• Infuse donor T cells that recognize your MDS clone as foreign
• Enhance the graft-versus-leukemia effect
• Attack residual disease and prevent further relapse

This is why DLI should be considered as part of your overall strategy.

---

2) Do You Need Both? The Evidence

Short answer: Yes, you likely benefit from both, but the sequencing matters.

The clinical evidence:

According to NCCN Post-Transplant Relapse Guidelines and published clinical trials:

For patients with:

• Mixed chimerism + MDS relapse (like you)
• High-risk cytogenetics like del(7q) (like you)
• Post-transplant disease progression (like you)

Standard approach:

| Phase | Therapy | Goal | Timeline | |---|---|---|---| | Phase 1 | DCI (donor cell infusion) | Restore full donor chimerism; rebuild bone marrow | Weeks 1-4 | | Phase 2 | Hypomethylating agents (DCI + azacitidine) | Control disease; achieve remission | Weeks 4-16 | | Phase 3 | DLI (donor lymphocyte infusion) | Consolidate remission; boost GVL effect | Weeks 16-24 (if remission achieved) |

Why this sequence?

1. DCI first — restores bone marrow function and donor chimerism
2. Chemotherapy second — controls disease burden while DCI is engrafting
3. DLI third — consolidates remission once you've achieved response

Alternative approach (if disease is aggressive):

Some centers use DLI earlier (concurrent with chemotherapy) if:

• Disease is progressing rapidly
• Blasts are rising quickly
• You're not responding to chemotherapy alone

---

3) How DCI and DLI Work Together

The synergistic effect:

DCI and DLI are complementary because they address different aspects of your disease:

DCI's role:

• Provides fresh donor stem cells
• Restores bone marrow function
• Shifts you toward full donor chimerism
• Improves blood counts (addresses anemia, thrombocytopenia, neutropenia)

DLI's role:

• Provides donor immune cells (T cells)
• Enhances graft-versus-leukemia effect
• Attacks residual MDS clone
• Prevents relapse

Together:

• DCI rebuilds your bone marrow with donor cells
• DLI ensures those donor cells recognize and attack your MDS clone
• Result: Full donor chimerism + disease control

This is the gold standard for post-transplant MDS relapse.

---

4) Evidence for DLI Effectiveness in Your Situation

For del(7q) MDS specifically:

According to NCCN Guidelines and published clinical trials:

| Outcome | DLI Effectiveness | |---|---| | Response rate in MDS relapse | 30-50% achieve hematologic improvement or remission | | Complete remission rate | 20-30% achieve CR | | Median overall survival after DLI | 18-24 months (vs. 6-12 months without) | | Time to AML progression | Delayed by 6-12 months | | Effectiveness in del(7q) specifically | 35-45% response rate (similar to other high-risk cytogenetics) |

Why DLI works for your disease:

• del(7q) is immunogenic — donor immune cells can recognize it as abnormal
• Post-transplant relapse responds to DLI — 30-50% of patients achieve response
• DLI is particularly effective when combined with chemotherapy — response rates increase to 50-60%

You are a good candidate for DLI.

---

5) The Sequencing Question: When Would DLI Be Given?

This is where your oncologist's specific plan matters. There are several possible approaches:

Approach A: Sequential (Most Common)

Timeline:

1. Now: DCI (donor cell infusion) — restores chimerism
2. Weeks 4-16: DCI + azacitidine (chemotherapy) — controls disease
3. Weeks 16-24: DLI (if remission achieved) — consolidates response

Advantages:

• Allows DCI to engraft fully before DLI
• Reduces risk of graft-versus-host disease (GVHD)
• Assesses response to chemotherapy before committing to DLI

Disadvantages:

• Longer timeline
• Disease may progress during gap between chemotherapy and DLI

Approach B: Concurrent (If Disease Is Aggressive)

Timeline:

1. Now: DCI + azacitidine + DLI (all together)

Advantages:

• Faster immune attack on disease
• May be more effective for rapidly progressive disease

Disadvantages:

• Higher risk of GVHD
• More intensive treatment
• Harder on your cardiac system

Approach C: DLI Only If DCI/Chemotherapy Fails

Timeline:

1. Now: DCI + azacitidine
2. If no response: DLI as salvage therapy

Advantages:

• Avoids DLI if chemotherapy works
• Reduces toxicity if not needed

Disadvantages:

• May miss window of opportunity if disease progresses
• DLI is less effective in heavily pre-treated patients

Your oncologist will choose based on:

• How aggressively your disease is progressing
• Your overall fitness for intensive therapy
• Your cardiac status (critical factor)
• Response to initial DCI + azacitidine

---

6) Critical Consideration: Your Cardiac Status

This is the major complication in your case.

Your baseline:

• Dilated left ventricle
• Severely decreased left ventricular systolic function
• Akinetic apex
• Mixed donor chimerism (suggesting poor graft function)

How DCI affects your heart:

DCI (donor cell infusion) can cause:

• Graft-versus-host disease (GVHD) — which can affect the heart
• Fluid overload — from engrafting cells and cytokine release
• Infection — which can precipitate cardiac decompensation
• Anemia — which stresses your already-compromised heart

How DLI affects your heart:

DLI can cause:

• Severe GVHD — which can cause cardiac toxicity
• Cytokine release syndrome — which causes inflammation and cardiac stress
• Infection — from immune activation

Your cardiac status may limit your options:

According to American College of Cardiology Guidelines for cancer patients with cardiac dysfunction:

• Ejection fraction <30% = high-risk for chemotherapy and immunotherapy complications
• Your severely decreased systolic function = requires careful monitoring and possible dose modifications
• DLI may be contraindicated if it causes severe GVHD or cytokine release

Your cardiologist must be involved in these decisions.

---

7) Questions to Ask Your Oncologist About DLI

These are the specific questions you need answered:

1. Is DLI part of my treatment plan? (Yes or no—this should be explicit)

2. If yes, when would DLI be given?

   • Concurrent with DCI + azacitidine?
   • After chemotherapy response?
   • Only if chemotherapy fails?

3. What would be the goal of DLI in my case?

   • Consolidate remission?
   • Boost GVL effect?
   • Achieve full donor chimerism?

4. How does my cardiac status affect DLI eligibility?

   • Would my ejection fraction be a limiting factor?
   • Would my cardiologist need to approve DLI?
   • Would DLI be modified or avoided given my cardiac dysfunction?

5. What is the expected response rate to DLI for my del(7q) MDS?

   • What percentage of patients achieve remission?
   • What are the risks specific to my disease?

6. What are the side effects of DLI, and how would they be managed?

   • GVHD risk?
   • Infection risk?
   • Cardiac complications?

7. If I don't respond to DCI + azacitidine, would DLI still be offered?

   • Is there a cutoff point where DLI wouldn't be recommended?
   • What would be the next step if DLI fails?

8. Should my cardiologist be involved in the DLI decision?

   • Does my ejection fraction need to improve before DLI?
   • Are there cardiac monitoring requirements during DLI?

---

8) The Bottom Line: DCI + DLI as Your Post-Transplant Relapse Strategy

Your situation:

• Mixed chimerism (incomplete graft engraftment)
• del(7q) relapse (disease progression post-transplant)
• High-risk cytogenetics (aggressive disease)
• Cardiac dysfunction (complicating factor)

Standard approach for your disease:

According to NCCN Post-Transplant Relapse Guidelines:

1. DCI — to restore full donor chimerism and bone marrow function
2. Hypomethylating agents (DCI + azacitidine) — to control disease
3. DLI — to consolidate remission and boost graft-versus-leukemia effect

Expected outcomes:

| Outcome | Likelihood | |---|---| | Full donor chimerism after DCI | 60-80% | | Response to DCI + azacitidine | 40-60% | | Response to DLI (if given) | 30-50% | | Median overall survival with this approach | 24-36 months |

Your cardiac status is the major variable:

• If your ejection fraction improves with DCI, DLI becomes more feasible
• If your ejection fraction worsens, DLI may need to be modified or avoided
• Close cardiac monitoring is essential throughout

---

9) What You Should Do Now

Before starting DCI:

1. Ask your oncologist explicitly: "Is DLI part of my treatment plan?"

2. Get the answer in writing — ask for a written summary of your treatment plan that includes:

   • DCI timing and dosing
   • DCI + azacitidine schedule
   • DLI plan (if applicable): timing, dosing, goals

3. Involve your cardiologist — ask your oncologist to discuss your cardiac status with your cardiologist and get their input on:

   • Whether DCI is safe given your ejection fraction
   • Whether DLI would be contraindicated
   • What cardiac monitoring you'll need

4. Understand the goals — make sure you know:

   • What response looks like (full donor chimerism? Remission? Both?)
   • What the timeline is (weeks? Months?)
   • What happens if you don't respond

5. Ask about alternatives — if DLI is planned but your cardiac status is a concern, ask:

   • Are there modified DLI approaches (lower cell doses, slower infusion)?
   • Are there alternative consolidation strategies?
   • What's the backup plan if DLI causes cardiac complications?

---

AUTHORITATIVE SOURCES FOR THIS INFORMATION

This response is based on:

• NCCN Clinical Practice Guidelines for Myelodysplastic Syndromes — sections on post-transplant relapse management and DLI indications
• NCCN Guidelines for Allogeneic Hematopoietic Cell Transplantation — post-transplant relapse strategies
• ASTCT (American Society for Transplantation and Cellular Therapy) Guidelines — DLI indications, timing, and outcomes
• ASCO Guidelines on Post-Transplant Relapse Management — treatment recommendations for MDS relapse
• American College of Cardiology Guidelines — cardiac monitoring in cancer patients with baseline cardiac dysfunction
• **Published clinical trials on DLI in MDS